High dose intravenous immunoglobulin for the treatment of autoimmune bullous diseases.

High dose intravenous immunoglobulin for the treatment of autoimmune bullous diseases. - High dose intravenous immunoglobulin for the treatment of autoimmune bullous diseases.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012601

Enrollment

Registered

2013-12-20

Start date

2013-04-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune bullous diseases

Interventions

Nihon-Pharmaceutical Co., Ltd. Kenketsu globenin-I for I.V. injection 400mg/kg/day x 5days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as autoimmune bullous disease not pemphigus vulgaris. Patients who did not improve with the existing treatment. Patients with severe infections or secondary effect. Severe case.

Exclusion criteria

Exclusion criteria: Patients of 5 years from the history of malignancy. Patients who have treated with steroid or immunosuppressant in 14 days. Patients with high-risk history of thrombosis, embolism. Patients who have treated with high dose intravenous immunoglobulin in 6 months. Patients who have history of secondary effect of blood products.

Design outcomes

Primary

Measure	Time frame
Pemphigus Disease Area Index: PDAI Pemphigus Score	—

Countries

Japan

Contacts

Public ContactYusuke HIRASAWA

Juntendo University School of Medicine Department of Dermatology

hirasawa@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026